ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
14.60
-1.22 (-7.71%)
Aug 14, 2025, 11:39 AM - Market open
ARS Pharmaceuticals Revenue
ARS Pharmaceuticals had revenue of $15.72M in the quarter ending June 30, 2025, with 3,043.40% growth. This brings the company's revenue in the last twelve months to $112.34M, up 22,367.80% year-over-year. In the year 2024, ARS Pharmaceuticals had annual revenue of $89.15M with 297,063.33% growth.
Revenue (ttm)
$112.34M
Revenue Growth
+22,367.80%
P/S Ratio
13.76
Revenue / Employee
$702,119
Employees
160
Market Cap
1.44B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
Dec 31, 2020 | 17.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SPRY News
- 23 hours ago - ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) - GlobeNewsWire
- 10 days ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results - GlobeNewsWire
- 27 days ago - EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - GlobeNewsWire